OM:EGTXBiotechs
Egetis Therapeutics (OM:EGTX) Stock Can Emcitate Justify Mounting Losses?
Egetis Therapeutics stock closed at SEK7.33 on the day of its Q2 report, after a steady 7 day climb of about 2% and a 3 month gain of about 16%. The headlines, however, sit squarely on the income statement. The company booked revenue of SEK17.4m for the quarter while posting a net loss of SEK108.9m as it pours money into Emcitate ahead of a potential United States launch.
In the very short term that loss looks heavy. Through a longer lens the key debate is whether today’s cash burn and high...